Ose Water AS is a Norwegian bottled water and bag-in-box water producer.The water source is Ose which provides high quality natural mineral water. The company aim to be in production for international sale in Q1 2019. Ose Water AS is a producer of natural mineral water from the Ose spring in Bygland municipality, Aust-Agder county in Norway.

Iterate is an ecosystem for digital innovation, and we like to describe ourselves as a company that builds companies. We contribute from A-Z when building, starting with creating concepts based on key insights to launching and improving products whilst living in the marketplace. We find the right team and work toward the company culture that enables us to deliver value to our customers quickly. The key to achieving this is reinvesting all our profits in the ideas of our employees, or selected entrepreneurs. Five years into this strategy, we own shares in fifteen ventures; all of which are showing promising results. Our 70 designers, developers, and product managers just moved into new locations in the center of Oslo. 
Close collaboration with our customers is key to our success. They provide domain know-how, and we provide tools, strategies, and experts. Together we uncover the best way that connects your strategy and idea with the market needs. Our goal is to achieve minimum risk and give our customers the best possible starting point for scaling, on their own, or in continued collaboration.

RESPINOR is a privately-owned medical device company, founded in Oslo, 2015. We have developed an objective measure of breathing for critically ill patients within intensive care. The technology provides precise, continuous and real-time information of diaphragm function, our main breathing muscle, to increase the quality of care and reducing costs. RESPINOR’s technology is the winner of Horizon 2020 both in phase I and II. We are addressing an unmet medical need because every breath counts.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Fishency Innovation can give access to the entire salmon industry to affordable equipment to count automatically sea lice in the cage. Monitoring sea lice is the key to controlling them, it is access to good decision support for optimized treatments and to a reliable tool to measure the efficiency of preventive measures and existing treatments. Today, sea lice are counted manually over 20 fish, every week, in each cage. It is labor-demanding, and the collected data are not reliable. Sustainability starts with good data.

Based in Kongsberg - the heart of the Subsea Valley - Kongsberg Ferrotech is utilizing world-leading competence to develop the first-ever automated solution, the Oktapous, for riser cleaning, NDT inspection, maintenance (coating), and structural repair (glass/carbon fiber reinforcement). The repair will be performed inside the patented Habitat - allowing for composite repairs subsea and in the splash zone while offering quality as if the repair was performed in a laboratory environment. The Oktapous will offer the client around 50% cost reduction, together with improved quality and significantly reduced HSE risk compare to existing solutions by removing the need for rope access, divers, and ROVs. Kongsberg Ferrotech is partly funded by the Malaysian-based oil and gas company, Petronas Charigali. This ensures us access to the market needs during development, an offshore platform for prototype testing, and the critical first client for market acceptance. Schedule highlights: • Development started in September 2015 • Stack-up/dry test in December 2017 • TRL4 testing submerged in February 2018 • Offshore testing on Petronas assets in Q3 2018 • Commercial operations in Q2-3 2019

MER er et norsk musikkselskap og artistrepresentant. Vår visjon er å bli bransjens beste på å kvalitetssikre, utvikle, fasiliteter og forvalte alle aspekter ved våre klienters karriere og virke. Selskapet har kompetanse og relevant erfaring i å tilby tjenester som management, promo, merkevarebygging og labefunksjoner. MER har de siste årene blitt et internasjonalt selskap med aktivitet over hele verden. Vår største klient, Alan Walker er i dag en av verdens største EDM-artister hvilket gir store muligheter for å bli kjent med en digital musikkverden.

Refyne så dagens lys i efteråret 2020 og er siden blevet et af de mest respekterede og seniortunge bureauer i Danmark med mere end 20+ ansatte Vi arbejder med skræddersyede og databaserede strategier inde for SEO, Paid Search & Social, Tracking, Webanalyse og Konverteringsoptimering. Vores målsætning er at være det mest kompetente bureau, ikke det største bureau. Det er vi gennem vores nytænkende løsninger og ved at levere forretningsmæssige resultater for vores kunder. Vi arbejder både med scale-ups og markedsledende virksomheder.

Medstart is a science-backed weight-loss platform, that seeks to change the way we do healthcare, by specifically challenging the way we handle obesity. We combine the effects of prescription GLP-1 medicine, personal lifestyle coaching and an interactive app that gives our members constant access to their entire team of healthcare professionals. We give our members the tools they need to lose weight, and always make sure to place out members right at the core of our business.

Søger du et job med fed energi? I b.energy er vi 32 kollegaer, der sammen knokler for at skabe Danmarks bedste kundeoplevelse. Og du kan komme med ombord. Hver dag arbejder vi på at gøre de grønne valg til de nemmest. Med over 14.000 kunder er vi langt fra de største, men heller ikke ubetydelige af størrelse. Vi er store nok til at tilbyde en af landet billigste elaftaler, give en strømlinet service og rejse nye skove i hele Danmark – men ikke så store, at vi ikke har tid til vores kunder. Er du på jagt efter nye udfordringer, så hold et skarpt øje med vores jobmuligheder – Det kan være, at det er lige netop dig, vi står og mangler. Vi vil sikre, at vores kunder CO2 impact fra elforbrug ikke blot kompenseres, men giver overskud.

We are a Finnish-based impact fund focusing on the Nordics. In alignment with founders of sustainable companies with environmental and social objectives, we invest and engage to make their impact operational, measurable, and profitable with a common goal to reduce the carbon footprint of consumption.

minimass™ was founded in 2021 to solve one of the biggest environmental problems facing the world today –the carbon footprint of construction. By delivering a low-carbon alternative to traditional concrete beams and saving clients up to 70% in carbon AND up to 50% in material costs, we have a solution that is urgently needed and ready to implement at a global scale.

Supercharging database performance to reduce server costs & server energy consumption. Vesiro is an early-stage startup that is developing an add-on to Elasticsearch to enable much better search performance. The product is in part based on our novel, patented search algorithms. Initial tests on data from Common Crawl (which is the same data used to train ChatGPT) shows that we can cut search times in Elasticsearch by 30-50% depending on search type used. The increase in search speed means that our software enables a more efficient use of servers in Elastic clusters, helping our customers save money on servers. It also means that the software reduces server energy consumption as fewer servers are needed to do the same amount of search. Vesiro was one of 20 companies to be accepted among 2500 companies applying globally to participate in the Norrsken Accelerator 2023. This means that we have been recognized as one of the world’s foremost high potential impact startups. The company is now closing its pre-seed investment round, which means that it has the capital to grow the team to accelerate software development. If you join our team, you will have the opportunity to take ownership in the company through stock options. As an early-stage startup, we have an exciting journey ahead. You will become a part of a small, tight-knit team that is turning innovative ideas into reality with the potential to have a real impact on the world. As one of the first hires, there will be great opportunities to grow in your role as the company grows. We work in central Gothenburg in the heart of the startup scene at Chalmers E-village, among tons of other startups and ecosystem actors.

We are solving digital guest service for the camping industri, and are now helping more than 60+ campgrounds in Denmark. We deliver a digital platform for the guests, and thereby making it easier for the guest to find the important information regarding their stay. At the same time, we save time for the owners, byt digitalizing and implementing our digital solutions.

6D Tape is unique, patented and active therapeutical tape which works in six directions. It features handles and is skin-friendly, making it well suited for lymphatic therapy, physical therapy, scar treatment and active self-care. The unique 6D handles allow manipulation that stimulates lymph flow, blood circulation, fasciae, scar tissue, muscles and joints. Treatment with 6D Tape will improve recovery from injury, ease joint and muscle pain, reduce nerve compression and swelling, and help with constricting scar tissue. 6D Tape has many therapeutic uses. 6D Tape is effective for treating back, neck and muscle pain, as well as swelling and joints. Manipulating the tape with the handles alleviates pain and reduces swelling by activating the body’s internal cleanup and healing mechanisms. The tape is also suited for treating surgical and traumatic scar tissue and swelling. For example, the tape is excellent at treating repetitive strain injuries, including golfer’s, mouse and tennis elbow, and constricting connective tissue (fascia). 6D Tape works well with patients having Lymphedema, which is a painful chronic condition that causes swelling of limbs and disabilities affecting more than 250 million people worldwide. It has considerable public health significance, characterized by a continuous need for medical treatment, many comorbidities and detrimental effect on patients’ social life and career. It is particularly common among breast cancer survivors with a prevalence of about 40%. The number of lymphedema cases is rising as the number of cancer survivors increases with more effective treatments. The life quality of these people keeps declining dramatically as there are no solutions to manage this condition effectively and live a normal life at the same time. 6D Tape Oy is developing an automated therapy tape system 6D Tape Pro designed for efficient self-care to alleviate lymphedema, as well as pain, scars, and swelling after surgeries and injuries. The tape can be conveniently worn under clothes without interrupting any daily activities. The automated pulsation provides a gentle pressure treatment in planned and natural lymph flow-mimicking intervals. This enables lymphedema patient’s body to function and drain lymph similar to normal body preventing edema. The solution will reduce overall treatment costs and burden on health care systems. Our patent-pending solutions are huge steps forward from any other treatment option available, enabling a lucrative positioning in a €7 billion market. The funding we are seeking is instrumental to take on the high-impact project closing the gap from technology prototype to a clinically validated product suited for mass market. Moreover, the new equity enables to secure enough operational capacity for a successful market launch.